API | insulin degludec

insulin degludec (tresiba) Report issue

Biologics Recombinant protein Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours, making it a once-daily basal insulin, that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
insulin degludec

More Chemistry

Pharmacology

Mechanisms of Action:
- Insulin receptor (Homo sapiens) ^UniProt
- Insulin-like growth factor 1 receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$25.1880 - $177.0467

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

ryzodeg ( insulin degludec (tresiba), insulin lispro (humalog) )

xultophy ( liraglutide (victoza), insulin degludec (tresiba) - other name: insulin degludec and liraglutide )

Organizations (40)

Research & Development (39)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Diabetes Mellitus

Experimental Indications - Clinical Trial Phases 1-4 (8)

Diabetes Mellitus ()

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 4)

Healthy Volunteers (Phase 1)

Hypoglycemia (Phase 4)

Kidney Failure, Chronic (Phase 4)

Liver Cirrhosis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 174
# of Trial Organizations: 39

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue